# Biofidelity

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biofidelity

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.biofidelity.com/
- Total disclosed funding: $36M
- Latest round: Series A (Dec 23, 2021)
- Investors on record: 5

## About

Based in Cambridge, UK, and founded in 2019 by co-founders Barnaby Balmforth (CEO) and Cameron Frayling, Biofidelity Ltd. operates as a provider of diagnostic assays for disease detection and monitoring to assess and implement therapies that enable the multiplexed detection of genetic mutations without performing DNA sequencing. In February 2024, Biofidelity Ltd. raised GBP 19.20 million in venture funding from Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures.

The company provides a wide range of genomic testing services, such as ASPYRE technology for actionable biomarker detection, ASPYRE-Lung for lung cancer biomarker analysis, and ENSPYRE for genomic precision testing.

## Funding rounds

- Series A, Dec 23, 2021, $23M — SBI Investment, Octopus Investments
- Series A, Apr 28, 2020, $12M — Agilent Technologies, Longwall Ventures, BlueYard Capital
- Seed, Jun 3, 2019, $0.9M — Longwall Ventures

## Investors

- Longwall Ventures (https://capitalatlas.ai/funds/longwall-ventures) — Seed, Series A
- Agilent Technologies — Series A
- BlueYard Capital (https://capitalatlas.ai/funds/blueyard-capital) — Series A
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series A
- Octopus Investments (https://capitalatlas.ai/funds/octopus-investments) — Series A